SEARCH:   Advanced

Blood, Vol. 113, Issue 26, 6567-6571, June 25, 2009 This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef Compassionate use of sorafenib in FLT3-ITD–positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation Blood Metzelder et al. 113: 6567 Supplemental materials for: Metzelder et al Files in this Data Supplement: Figure S1. Serial blood counts and intracellular phospho-Stat-5 measurements under sorafenib treatment (patient #4) (JPG, 294 KB) - Rapid HR and a partial recovery of thrombocytopenia were seen upon exposure to sorafenib. Sorafenib was stopped in neutropenic sepsis before day 50. The patient died on day +58 because of sepsis. Middle panel: fluorescence-activated cell sorting histogram illustrating a left shift (decrease) in intracellular Stat-5 phosphorylation 7 days after commencing sorafenib (green line), when compared to baseline (day 0, red line). Stat-5 phosphorylation was measured by gating on the blasts. This Article Abstract Full Text Services Email this article to a friend Alert me to new issues of the journal Rights and Permissions Citing Articles Citing Articles via CrossRef

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020